The oxidation hypothesis of atherosclerosis: An update

Annals of Clinical and Laboratory Science

Volumn 27, Issue 1, 1997, Pages 1-10

  Westhuyzen, Justin ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIOXIDANT;

ARTERY INTIMA; ATHEROGENESIS; ATHEROSCLEROSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTHESIS; LIPID OXIDATION; LIPOPROTEIN METABOLISM; MACROPHAGE ACTIVATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW;

ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; ARTERIOSCLEROSIS; CHOLESTEROL; DIET; FREE RADICALS; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MODELS, CHEMICAL;

EID: 0031032586     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88: 1785-92.
2. Steinberg D, Witztum JL. Lipoproteins and atherogenesis. Current concepts. JAMA 1990;264:3047-52.
3. Steinberg D. Lipoproteins and atherosclerosis: a look back and a look ahead. Arteriosclerosis 1983;3:283-301.
4. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med 1989;320:915-24.
5. Leake DS. Oxidised low density lipoproteins and atherogenesis. Br Heart J 1993;69:476-8.
6. Aviram M. Oxidative modification of low density lipoprotein and its relation to atherogenesis. Isr J Med Sci 1995;31:241-249.
7. Frei B. Cardiovascular disease and nutrient antioxidants: role of low-density lipoprotein oxidation. Critical Reviews in Food Science & Nutrition 1995;35:83-98.
8. Witztum JL. Role of oxidised low density lipoprotein in atherogenesis. Br Heart J 1993;69(Suppl):S12-18.
9. Daugherty A, Roselaar SE. Lipoprotein oxidation as a mediator of atherogenesis: insights from pharmacological studies. Cardiovasc Res 1995;29:297-311.
10. Holvoet P, Collen D. Oxidised lipoproteins in atherosclerosis and thrombosis. FASEB J 1994;8:1279-84.
11. Frei B. Reactive oxygen species and antioxidant vitamins: mechanisms of action. Am J Med 1994;97(suppl 3A):5S-13S.
12. Chang GJ, Woo P, Honda HM, Ignarro LJ, Berliner JA, Demer LL. Oxidation of LDL to a biologically active form by derivatives of nitric oxide and nitrate in the absence of superoxide. Dependence on pH and oxygen. Arteriosclerosis Thromb 1994;14:1808-14.
13. Campbell WB. Lipid-derived autacoids: Eicosanoids and platelet-activating factor. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. New York: Pergamon Press, 1990;600-617.
14. Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcart MK. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J Clin Invest 1995;96:504-10.
15. Darley-Usmar VM, Hogg N, O'Leary VJ, Wilson MT, Moncada S. The simultaneous generation of superoxide and nitric oxide can initiate lipid peroxidation in human low density lipoprotein. Free Radic Res Commun 1992;17:9-20.
16. Van der Vliet A, Smith D, O'Neill CA, Kaur H, Darley-Usmar VM, Cross CE, Halliwell B. Interactions of peroxynitrite with human plasma and its constituents: oxidative damage and antioxidant depletion. Biochem J 1994;303:295-301.
17. 2-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite. Circ Res 1995;77:335-41.
18. Esterbauer H, Jurgens G, Quehenberger Q, Koller E. autooxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res 1987;28:495-509.
19. Carpenter KL, Wilkins GM, Fussell B, Ballantine JA, Taylor SE, Mitcinson MJ, Leake DS. Production of oxidized lipids during modification of low-density lipoprotein by macrophages or copper. Biochem J 1994;304:625-33.
20. Folcik VA, Cathcart MK. Predominance of esterified hydroperoxy-linoleic acid in human monocyteoxidised LDL. J Lipid Res 1994;35:1570-82.
21. Blanche D, Rodriguez C, Davignon J. Enhanced susceptibility of cholesteryl sulfate-enriched low density lipoproteins to copper-mediated oxidation. FEBS Lett 1995;362:197-200.
22. Blanche D, Rodriguez C, Davignon J. Pro-oxidant effects of 7-hydroperoxycholest-5-en-3β-ol on the copper-initiated oxidation of low density lipoprotein. FEBS Lett 1995;357:135-9.
23. Chisolm GM, Ma G, Irwin KG, Martin LL, Gunderson KG, Linberg LF, Morel DW, DiCorleto PE. 7 beta-hydroperoxycholest-5-en 3 beta-ol, a component of human atherosclerotic lesions., is the primary cytotoxin of oxidized human low density lipoprotein. Proc Natl Acad Sci USA 1994;91:11452-6.
24. Thomas JP, Kalyanaraman B, Girotti AW. Involvement of preexisting, lipid hydroperoxides in Cu (2+)stimulated oxidation of low-density lipoprotein. Arch Biochem Biophys 1994;315:244-54.
25. Fogelman AM, Haberland ME, Seager J, Hokom M, Edwards PA. Factors regulating the activities of the low density lipoprotein receptor and the scavenger receptor on human monocyte-macrophages. J Lipid Res 1981;22:1131-41.
26. Sparrow CP, Parthasarathy S, Steinberg D. A macrophage receptor that recognises oxidised LDL but not acetylated LDL. J Biol Chem 1989;264:2599-2604.
27. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995;91:2488-2496.
28. Penn MS, Chisolm GM. Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis 1994;108:S21-S29.
29. Fuhrman B, Oiknine J, Aviram M, Iron induces lipid peroxidation in cultured macrophages, increases their ability to oxidatively modify LDL, and affects their secretory properties. Atherosclerosis 1994;111:65-78.
30. Suzukawa M, Abbey M, Clifton P, Nestel PJ. Effects of supplementation with vitamin E on the uptake of low density lipoprotein and the stimulation of cholesteryl ester formation in macrophages. Atherosclerosis 1994;110:77-86.
31. Dushkin MI: Schwartz YS. Effect of verapamil and nifedipine on cholesteryl ester metabolism and low-density lipoprotein oxidation in macrophages. Biochem Pharmacol 1995;49:389-97.
32. Sutherland WH. Oxidation of heparin-isolated LDL by hemin. The effect of serum components. Arterioscler Thromb 1994;14:1966-75.
33. Dobrian A, Simionescu M. Irreversibly glycated albumin alters the physio-chemical characteristics of low density lipoproteins of normal and diabetic subjects. Biochim Biophys Acta 1995;1270:26-35.
34. Jimi S, Sakata N, Matunaga A, Takebayashi S. Low density lipoproteins bind more to type I and III collagens by negative charge-dependent mechanisms than to type IV and V collagens. Atherosclerosis 1994; 107:109-16.
35. Salonen JT, Korpela H, Nyyssonen K, Porkkala E, Tuomainen TP, Belcher JD, Jacobs DR Jr., Salonen R. Lowering of body iron stores by blood letting and oxidation resistance of serum lipoproteins: a randomized cross-over trial in male smokers. J Intern Med 1995;237:161-8.
36. Craig WY, Poulin SE, Palomaki GE, Neveux LM, Richie RF, Ledue TB. Oxidation-related analytes and lipid and lipoprotein concentrations in healthy subjects. Arterioscler Thromb Vasc Biol 1995;15:733-9.
37. Berwanger CS, Jeremy JY, Stansby, G. Homocysteine and vascular disease. Br J Surg 1995;82:726-731.
38. Manilow MR. Plasma homocyst(e)ine and arterial occlusive diseases: a mini-review. Clin Chem 1995;41: 173-6.
39. Sarkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986;77:1370-6.
40. Hirano K, Ogihara T, Miki M, Yashuda H, Tamai H, Kawamura N, Mino M. Homocysteine induces iron-catalyzed lipid peroxidation of low-density lipoprotein that is prevented by alpha-tocopherol. Free Radic Res 1994;21:267-76.
41. Blom HJ, Kleinveld HA, Boers GH, Demackar PN, Hak-Lemmers HL, Te Poele-Pothoff MT, Trijbels JM. Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinaemia. Eur J Clin Invest 1995;25:149-54.
42. Dudman NPB,Wilcken DEL, Stocker R. Circulating lipid hydroperoxide levels in human hyperhomocysteinemia. Relevance to development of atherosclerosis. Arterioscler Thromb 1993;13:512-6.
43. Oosenbrug GS, Mensink RP, Hornstra G. Effects of fish oil and vitamin E supplementation on copper-catalysed oxidation of human low density lipoprotein in vitro. Eur J Clin Nutr 1994;48:895-8.
44. Princen HM, van Duyenvoorde W, Buytenhek R, van der Laarse A, van Poppel G, Gevers Leuven JA, van Hinsbegh VW. Supplementation with low doses of vitamin E protects LDL from lipid peroxidation in men and women. Arterioscler Thromb Vasc Biol 1995; 15:325-33.
45. Suzukawa M, Ishikawa T, Yoshida H, Nakamura H. Effect of in-vivo supplementation with low-dose vitamin E on susceptibility of low-density lipoprotein to oxidative modification. J Am Coll Nutr 1995;14:46-52.
46. Esterbauer H, Dieber-Rotheneder M, Striegl G, Waeg G. Role of vitamin E in preventing the oxidation of low-density lipoprotein. Am J Clin Nutr 1991;53: 314S-21S.
47. Nyyssonen K, Porkkala E, Salonen R, Korpela H, Salonen JT. Increase in oxidation resistance of atherogenic serum lipoproteins following antioxidant supplementation: a randomized double-blind placebo-controlled clinical trial. Eur J Clin Nutr 1994;48:633-42.
48. Croft KD, Williams P, Dimmitt S, Abu-Amsha R, Beilin LJ. Oxidation of low-density lipoproteins: effect of antioxidant content, fatty acid composition and intrinsic phospholipase activity on susceptibility to metal ion-induced oxidation. Biochim Biophys Acta 1995;1254:250-256.
49. Gaziano JM, Hatta A, Flynn M, Johnson EJ, Krinsky NI, Ridker PM, Hennekens CH, Frei B. Supplementation with beta-carotene in vivo and in vitro does not inhibit low density lipoprotein oxidation. Atherosclerosis 1995;112:187-95.
50. Maiorino M, Zamburlini A, Roveri A, Ursini F. Copper-induced lipid peroxidation in liposomes, micelles, and LDL: which is the role of vitamin E? Free Radic Biol Med 1995;18:67-74.
51. Bowry VW, Mohr D, Cleary J, Stocker R. Prevention of tocopherol-mediated peroxidation in ubiquinol-10-free human low density lipoprotein. J Biol Chem 1995;270:5756-63.
52. Morel DW, de la Llera-Moya M, Friday KE. Treatment of cholesterol-fed rabbits with dietary vitamins E and C inhibits lipoprotein oxidation but not development of atherosclerosis. J Nutr 1994;124:2123-30.
53. Kleinveld HA, Hak-Lemmers HL, Hectors MP, de Fouw NJ, Demacker PN, Stalenhoef AF. Vitamin E and fatty acid intervention does not attenuate the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 1995;15:290-7.
54. Lafont AM, Chai YC, Cornhill JF, Whitlow PL, Howe PH, Chisolm GM. Effect of α-tocopherol on restenosis after angioplasty in a model of experimental atherosclerosis. J Clin Invest 1995;95:1018-25.
55. Murohara T, Kugiyama K, Ohgushi M, Sugiyama S, Ohta Y, Yasue H. LPC in oxidized LDL elicits vaso-constriction and inhibits endothelium-dependent relaxation. Am J Physiol 1994;267;H2441-9.
56. Gilligan DM, Sack MN, Guetta V, Casino PR, Quyyumi AA, Rader DJ, Panza JA, Cannon RO 3rd. Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. J Am Coll Cardiol 1994;24:1611-17.
57. McDowell IF, Brennan GM, McEneny J, Young IS, Nicholls DP, McVeigh GE, Bruce I, Trimble ER, Johnston CD. The effect of probucol and vitamin E treatment on the oxidation or low-density lipoprotein and forearm vascular responses in humans. Eur J Clin Invest 1994;24:759-65.
58. Zeiden B, Wuttge DM, Karlberg BE, Olsson AG. Effects of in vitro addition of captopril on copper-induced low density lipoprotein oxidation. Br J Clin Pharmacol 1995;39:201-3.
59. Clearfield MB, Lee N, Armstrong L, DeFazio P, Kudchodkar BJ, Lacko AG. The effect of captopril on the oxidation of plasma lipoproteins. Pharmacol Toxicol 1994;75:218-21.
60. Keidar S, Kaplan M, Shapira C, Brook JG, Aviram M. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis 1994; 107:71-84.
61. Lupo E, Locher R, Weisser B, Vetter W. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol. Biochem Biophys Res Commun 1994;203:1803-8.
62. Bredie SJ, de Bruin TW, Demacker PN, Kastelein JJ, Stalenhoef AF. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability, Am J Cardiol 1995; 75:348-53.
63. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986;77: 641-4.
64. Walldius G, Erikson U, Olsson AG, Berstrand L, Hadell K, Johansson J, Kaijser L, Lassvik C, Molgaard J, Nilsson S, Schafer-Elinder L, Stenport G, Holme I. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875-83.
65. Parthasarathy S, Morales AJ, Murphy AA. Antioxidant: a new role for RU-486 and related compounds. J Clin Invest 1994;94:1990-5.
66. Taniguchi S, Yanase T, Kobayashi K, Takayanagi R, Haji M, Umeda F, Nawata H. Catechol estrogens are more potent antioxidants than estrogens for the Cu(2+)-catalyzed oxidation of low or high density lipoprotein: antioxidative effects of steroids on lipoproteins. Endocrine J 1994;41:605-11.
67. Bittolo-Bon G, Cazzolato G, Avogaro P. Probucol protects low-density lipoproteins from in vitro and in vivo oxidation. Pharmacol Res 1994;29:337-44.
68. Selley ML, Czeti AL, McGuiness JA, Ardlie NG. Dipyridamole inhibits the oxidative modification of low density lipoprotein. Atherosclerosis 1994;111: 91-7.
69. Visioli F, Galli C. Oleuropein protects low density lipoprotein from oxidation. Life Sci 1994;55:1965-71.
70. Apanay DC, Neylan JF, Ragab MS, Sgoutas DS. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation 1994;58:663-9.
71. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease, Lancet 1992;339:1523-26.
72. Fuhrman B, Lavy A, Aviram M. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. Am J Clin Nutr 1995;61:549-54.
73. Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of oxidation of human low density lipoprotein by phenolic substances in red wine. Lancet 1993;341:454-7.
74. Miura S, Watanabe J, Tomita T, Sano M, Tomita I. The inhibitory effects of tea polyphenols (flavan-3-ol derivatives) on Cu2+ mediated oxidative modification of low density lipoprotein. Biol Pharmacol Bull 1994; 17:1567-72.
75. Gey KF. Prospects for the prevention of free radical disease, regarding cancer and cardiovascular disease. Br Med Bull 1993;49:679-99.
76. Oliver MF. Antioxidant nutrients, atherosclerosis, and coronary heart disease. Br Heart J 1995;73:299-301.
77. Greenberg ER, Sporn MB. Antioxidant vitamins, cancer, and cardiovascular disease. N Engl J Med 1996; 334:1189-90.
78. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. New Engl J Med 1993;328:1450-6.
79. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. New Engl J Med 1996;334:1156-62.
80. Stampfer MJ, Hennekens GH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. New Engl J Med 1993;328:1444-9.
81. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. New Engl J Med 1996;334:114.5-9.
82. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. New Engl J Med 1996;334:1150-5.
83. Nenseter MS, Volden V, Berg T, Drevon CA, Ose L, Tonstad S. No effect of beta-carotene supplementation on die susceptibility of low density lipoprotein to in vitro oxidation among hypercholesterolaemic, post-menopausal women. Scand J Clin Lab Invest 1995;55: 477-85.
84. Andrews B, Burnand K, Paganga G, Browse N, Rice-Evans C, Sommerville K, Leake D, Taub N. Oxidis- ability of low density lipoproteins in patients with carotid or femoral artery atherosclerosis. Atheroscle- rosis 1995;112:77-84.
85. Maggi E, Perani G, Falaschi F, Frattoni A, Martignoni A, Finardi G, Stefano PL, Simeone F, Paolini G, DeVecchi E, et al. [Autoantibodies against oxidised low density lipoproteins in patients with coronary disease] [French]. Presse Medicale 1994;23:1158-62.
86. Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidised LDL. Arterioscler Thromb Vasc Biol 1995; 15:441-5.
87. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994; 46:869-76.
88. Puurunen M, Manttari M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, Vaarala O, Aho K, Palosuo T. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154:2605-9.
89. Kaysen GA. Hyperlipidemia of chronic renal failure. Blood Purif 1994;12:60-7.
90. Loughrey CM, Young IS, McEneny J, McDowell IF, McMaster C, McNamee PT, Trimble ER. Oxidation of low density lipoprotein in patients on regular haemodialysis. Atherosclerosis 1994;110:185-93.